Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding

References

• Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumours. Lancet Oncol.5(11), 681–689 (2004).
   PubMed Web of Science ®Google Scholar
• Restifo NP, Rosenberg SA. Use of standard criteria for assessment of cancer vaccines. Lancet Oncol.6(1), 3–4 (2005).
   Google Scholar
• Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and Phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother.53(3), 249–255 (2004).
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest.23(5), 413–419 (2005).
   PubMed Web of Science ®Google Scholar
• Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol.90, 175–213 (2006).
   PubMed Web of Science ®Google Scholar
• Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature437(7055), 141–146 (2005).
   PubMed Web of Science ®Google Scholar
• de Jong A, van Poelgeest MI, van der Hulst JM et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res.64(15), 5449–5455 (2004).
   PubMed Web of Science ®Google Scholar
• Piersma SJ, Welters MJ, van der Hulst JM et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int. J. Cancer122(3), 486–494 (2008).
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Piersma SJ, de Jong A et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl Acad. Sci. USA104(29), 12087–12092 (2007).
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Menon AG, Redeker A et al. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. Int. J. Cancer107(3), 425–433 (2003).
   PubMedGoogle Scholar
• van der Burg SH, de Cock K, Menon AG et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur. J. Immunol.31(1), 146–155 (2001).
   PubMed Web of Science ®Google Scholar
• Agarwal A, Rani M, Saha GK et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol. Invest.32(1–2), 17–30 (2003).
   PubMed Web of Science ®Google Scholar
• Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J. Immunol.174(5), 2661–2670 (2005).
   PubMed Web of Science ®Google Scholar
• Wang HY, Lee DA, Peng G et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity20(1), 107–118 (2004).
   PubMed Web of Science ®Google Scholar
• Wang HY, Wang RF. Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. Microbes Infect.7(7–8), 1056–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of γ-interferon-secreting cells. J. Immunol. Methods110(1), 29–36 (1988).
   PubMed Web of Science ®Google Scholar
• Herr W, Protzer U, Lohse AW, Gerken G, Meyer zum Buschenfelde KH, Wolfel T. Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J. Infect. Dis.178(1), 260–265 (1998).
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Ressing ME, Kwappenberg KM et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int. J. Cancer91(5), 612–618 (2001).
   PubMed Web of Science ®Google Scholar
• Assenmacher M, Schmitz J, Radbruch A. Flow cytometric determination of cytokines in activated murine T helper lymphocytes: expression of interleukin-10 in interferon-γ and in interleukin-4-expressing cells. Eur. J. Immunol.24(5), 1097–1101 (1994).
   PubMedGoogle Scholar
• Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods159(1–2), 197–207 (1993).
   PubMed Web of Science ®Google Scholar
• Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science274(5284), 94–96 (1996).
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B, Gualberto A, Glaspy JA et al. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin. Cancer Res.12(1), 107–116 (2006).
   PubMed Web of Science ®Google Scholar
• Speiser DE, Pittet MJ, Guillaume P et al. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J. Immunother. (1997)27(4), 298–308 (2004).
   PubMedGoogle Scholar
• Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D’Souza MP. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retroviruses21(1), 68–81 (2005).
   PubMed Web of Science ®Google Scholar
• Janetzki S, Cox JH, Oden N, Ferrari G. Standardization and validation issues of the ELISPOT assay. Methods Mol. Biol.302, 51–86 (2005).
   PubMedGoogle Scholar
• Janetzki S, Panageas KS, Ben-Porat L et al. Results and harmonization guidelines from two large-scale international ELISPOT proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother.57(3), 303–315 (2007).
   Google Scholar
• Britten CM, Gouttefangeas C, Welters MJ et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. (2007).
   Google Scholar
• Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. (1997), 30(1), 1–15 (2007).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother.25(2), 97–138 (2002).
   PubMed Web of Science ®Google Scholar
• Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol. Immunother.57(3), 285–288 (2007).
   PubMed Web of Science ®Google Scholar
• Smyth LJ, Van Poelgeest MI, Davidson EJ et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res.10(9), 2954–2961 (2004).
   PubMed Web of Science ®Google Scholar
• Baldwin PJ, Van Der Burg SH, Boswell CM et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res.9(14), 5205–5213 (2003).
   PubMed Web of Science ®Google Scholar
• Davidson EJ, Boswell CM, Sehr P et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res.63(18), 6032–6041 (2003).
   PubMed Web of Science ®Google Scholar
• Walden P. Therapeutic vaccination for the treatment of malignant melanoma. Recent Results Cancer Res.176, 219–227 (2007).
   PubMedGoogle Scholar
• Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev. Vaccines4(3), 329–350 (2005).
   PubMed Web of Science ®Google Scholar
• Darrah PA, Patel DT, De Luca PM et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med.13(7), 843–850 (2007).
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Bernsen MR, Lesterhuis WJ et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol.23(24), 5779–5787 (2005).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol.3(11), 991–998 (2002).
   PubMed Web of Science ®Google Scholar
• Rohrer JW, Barsoum AL, Dyess DL, Tucker JA, Coggin JH Jr. Human breast carcinoma patients develop clonable oncofetal antigen- specific effector and regulatory T lymphocytes. J. Immunol.162(11), 6880–6892 (1999).
   PubMed Web of Science ®Google Scholar
• Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood107(2), 628–636 (2006).
   PubMed Web of Science ®Google Scholar
• Viguier M, Lemaitre F, Verola O et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol.173(2), 1444–1453 (2004).
   PubMed Web of Science ®Google Scholar
• Piersma SJ, Jordanova ES, van Poelgeest MI et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res.67(1), 354–361 (2007).
   PubMed Web of Science ®Google Scholar
• Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology103(4), 449–457 (2001).
   PubMed Web of Science ®Google Scholar
• Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J. Immunol.167(5), 2972–2978 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med.348(3), 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Yu P, Lee Y, Liu W et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med.201(5), 779–791 (2005).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10(9), 942–949 (2004).
   PubMed Web of Science ®Google Scholar
• Diederichsen AC, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol. Immunother.52(7), 423–428 (2003).
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA102(51), 18538–18543 (2005).
   PubMed Web of Science ®Google Scholar
• Casares N, Arribillaga L, Sarobe P et al. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol.171(11), 5931–5939 (2003).
   PubMed Web of Science ®Google Scholar
• Welters MJ, Kenter G, Piersma SJ et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by an HPV16 E6 and E7 long-peptide vaccine. Clin. Cancer Res.14, 178–187 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol.175(9), 6169–6176 (2005).
   PubMed Web of Science ®Google Scholar
• Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115(3), 739–746 (2005).
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115(12), 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Monsurro V, Wang E, Panelli MC et al. Active-specific immunization against melanoma: is the problem at the receiving end? Semin. Cancer Biol.13(6), 473–480 (2003).
   PubMed Web of Science ®Google Scholar
• Marincola FM, Ferrone S. Immunotherapy of melanoma: the good news, the bad ones and what to do next. Semin. Cancer Biol.13(6), 387–389 (2003).
   PubMed Web of Science ®Google Scholar
• Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol.24(6), 335–342 (2003).
   PubMed Web of Science ®Google Scholar
• Ganss R, Limmer A, Sacher T, Arnold B, Hammerling GJ. Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol. Rev.169, 263–272 (1999).
   Google Scholar
• Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res.62(13), 3581–3586 (2002).
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Aulakh KS, Nair RE et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J. Immunol.177(10), 6962–6973 (2006).
   PubMed Web of Science ®Google Scholar
• Wall EM, Milne K, Martin ML, Watson PH, Theiss P, Nelson BH. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res.67(13), 6442–6450 (2007).
   Google Scholar
• Kenter G, Welters MJ, Valentijn ARPM et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high risk HPV16 in end stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res.14, 169–177 (2008).
   PubMed Web of Science ®Google Scholar
• Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized Phase III studies with active cancer immunotherapies – outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine25(Suppl. 2), B97–B109 (2007).
   PubMed Web of Science ®Google Scholar